✦ LIBER ✦

Comparison of potential biological markers cathepsin B, cathepsin L, stefin A and stefin B with urokinase and plasminogen activator inhibitor-1 and clinicopathological data of breast carcinoma patients

✍ Scribed by Nataša Levičar; Janko Kos; Andrej Blejec; Rastko Golouh; Ivan Vrhovec; Snježana Frkovič-Grazio; Tamara T Lah

Book ID: 114238064
Publisher: Elsevier Science
Year: 2002
Tongue: English
Weight: 113 KB
Volume: 26
Category: Article
ISSN: 0361-090X
DOI: 10.1016/s0361-090x(02)00015-6

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Tumor marker utility and prognostic rele

Tumor marker utility and prognostic relevance of cathepsin B, cathepsin L, urokinase-type plasminogen activator, plasminogen activator inhibitor type-1, CEA and CA 19-9 in colorectal cancer

✍ László Herszényi; Fabio Farinati; Romilda Cardin; Gábor István; László D Molnár; 📂 Article 📅 2008 🏛 BioMed Central 🌐 English ⚖ 390 KB

Prediction of pelvic lymph node metastas

Prediction of pelvic lymph node metastasis by the ratio of cathepsin B to stefin A in patients with prostate carcinoma

✍ Akhouri A. Sinha; Barry J. Quast; Michael J. Wilson; Eduardo T. Fernandes; Prata 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 521 KB

## Abstract ## BACKGROUND Pathologic grade and/or histologic score, extraprostatic extension indicated by invasion of the prostatic capsule, margin, and/or seminal vesicles by prostate cancer cells, serum total prostate‐specific antigen (PSA), free PSA, complexed PSA levels and/or their ratios, re

Matrix metalloproteinases, but not cathe

Matrix metalloproteinases, but not cathepsins B, H, and L or their inhibitors in peripheral blood of patients with rheumatoid arthritis are potentially useful markers of disease activity

✍ G. Keyszer; I. Lambiri; M. Keysser; C. Keysser; R. Nagel; G.-R. Burmester; K. Ju 📂 Article 📅 1998 🏛 Springer-Verlag 🌐 German ⚖ 85 KB